

Reporting Entity & Study Name	Total Amount
<b>PFIZER INC.</b>	<b>\$175,193,142.07</b>
A MULTICENTER RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED PARALLEL GROUP STUDY ASSESSING THE SAFETY AND EFFICACY OF TOFACITINIB IN HOSPITALIZED PARTICIPANTS WITH COVID19 PNEUMONIA WHO ARE RECEIVING STANDARD OF CARE THERAPY	\$159,908.50
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS	\$172,094,871.86
A PHASE 1B 2PART DOUBLEBLIND PLACEBOCONTROLLED SPONSOROPEN STUDY TO EVALUATE THE SAFETY TOLERABILITY AND PHARMACOKINETICS OF SINGLE ASCENDING 24HOUR PART 1 AND EXTENDED 120HOUR PART 2 INTRAVENOUS INFUSIONS OF PF07304814 IN HOSPITALIZED PARTICIPANTS WITH COVID19	\$205,021.20
A RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED TRIAL TO EVALUATE THE EFFICACY OF RAMIPRIL TO PREVENT ICU ADMISSION MECHANICAL VENTILATION OR DEATH IN PERSONS WITH COVID19	\$1,285,479.81
ACQUISITION OF COV2 CLINICAL ISOLATES	\$30,000.00
ASSESSMENT AND VALIDATION OF SEVERE COVID19 ILLNESS ENDPOINTS SUPPORT FOR A REALWORLD REGULATORY STUDY TO CONTEXTUALIZE FINDINGS FROM A CLINICAL TRIAL FOR PFIZER BNT162 SARSCOV2 VACCINE CANDIDATE	\$116,000.00
COVID 19OPENLABEL STUDY OF MARAVIROC IN HOSPITALIZED INDIVIDUALS DIAGNOSED WITH SARSCOV2	\$7,672.70
COVID19 VACC CLINICAL PUBLICATION PROGRAM	\$34,700.00
INVESTIGATION OF TOFACITINIB TO MITIGATE THE IMPACT OF COVID19 ITOMIC IN MODERATE SARSCOV2 MODERATE ITOMIC	\$791,602.90
REPORTER SARSCOV2 VIRUS NEUTRALIZATION ASSAY	\$420,000.00
SIROLIMUS TREATMENT IN HOSPITALIZED PATIENTS WITH COVID19 PNEUMONIA	\$47,885.10
<b>Regeneron Pharmaceuticals, Inc.</b>	<b>\$100,184,339.00</b>
A Master Protocol Assessing the Safety, Tolerability, and Efficacy of Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies for the Treatment of Ambulatory Patients With COVID-19	\$60,614,806.68
A Master Protocol Assessing the Safety, Tolerability, and Efficacy of Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies for the Treatment of Hospitalized Patients With COVID-19	\$7,346,486.79
A Phase 1, Randomized, Double-Blind, Placebo-Controlled Study Assessing the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Repeated Subcutaneous Doses of Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies (REGN10933+REGN10987) in Adult Volunteers	\$6,986,592.18
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Assessing the Efficacy and Safety of Anti-Spike SARS-CoV-2 Monoclonal Antibodies in Preventing SARS-CoV-2 Infection in Household Contacts of Individuals Infected With SARS-CoV-2	\$10,335,840.20
An Adaptive Phase 2/3, Randomized, Double-Blind, Placebo-Controlled Study Assessing Efficacy and Safety of Sarilumab for Hospitalized Patients With COVID-19	\$14,702,887.85
Characterization of the Molecular and Cellular Phenotype of Key Cell Immune Populations in COVID-19 Patients	\$18,725.00
scRNAseq from urine in COVID-19 patients including sarliumab treated patients	\$130,513.00
Study of factors influencing severity of COVID-19 disease	\$48,487.30

<b>AstraZeneca Pharmaceuticals LP</b>	<b>\$67,253,239.14</b>
A Phase 2, Open Label, Randomized Study of the Efficacy and Safety of Acalabrutinib with Best Supportive Care Versus Best Supportive Care in Subjects Hospitalized with COVID 19	\$350,984.86
A Phase III Randomized Double-blind Placebo-controlled Multicenter Study in Adults to Determine the Safety Efficacy and Immunogenicity of AZD1222 a Non-replicating ChAdOx1 Vector Vaccine for the Prevention of COVID-19	\$50,948,966.51
An Open-label, Multiple-dose Study to Evaluate the Pharmacokinetics, and Safety and Tolerability of Acalabrutinib Suspension Delivered via Nasogastric Tube, Coadministered With a Proton-pump Inhibitor, in Participants Hospitalized With COVID-19	\$22,420.00
Randomized Phase 2 Trial of Acalabrutinib Standard Treatment versus Standard Treatment alone for COVID 19 Illness Requiring Hospitalization	\$3,006,264.00
Study testing Dapagliflozin in respiratory failure in relation to COVID 19	\$12,924,603.77
<b>Janssen Research &amp; Development, LLC</b>	<b>\$55,278,713.67</b>
54179060COV2001 Randomized Double-Blind Phase 2 Trial of Ibrutinib versus Standard Treatment for COVID-19 Illness Requiring Hospitalization with Safety Lead-In	\$11,661.30
A Phase 2 Double-blinded, Placebo-controlled, Group Sequential Design, Study to Evaluate the Efficacy and Safety of Ustekinumab in High-risk Outpatients with Confirmed COVID-19	\$10,000.00
A Randomized, Double-blind, Placebo Controlled Phase 2 Clinical Study to Evaluate the Efficacy and Safety of Itraconazole (SPORANOX) for the Treatment of Participants With COVID-19	\$27,050.00
A Randomized, Double-blind, Placebo-controlled Phase 1/2a Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Ad26COVS1 in Adults Aged 18 to 55 Years Inclusive and Adults Aged 65 Years and Older	\$2,385,361.67
A Study of Ad26.COVS2 for the Prevention of SARS-CoV-2-Mediated COVID-19 in Adult Participants	\$39,990,376.46
A Study of Ad26.COVS2 for the Prevention of SARS-CoV-2-mediated COVID-19 in Adults	\$7,506,520.28
A Study of Ad26.COVS2 in Adults (COVID-19)	\$3,479,348.73
A Study of Rivaroxaban to Reduce the Risk of Major Venous and Arterial Thrombotic Events, Hospitalization and Death in Medically Ill Outpatients With Acute, Symptomatic Coronavirus Disease 2019 (COVID-19) Infection	\$122,170.20
COVID-19 Phase 3 Vaccine Trial Readiness Cohorts - Rutgers	\$213,904.00
Phase 2, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Infliximab in Confirmed Severe or Critical COVID-19	\$24,000.00
Phase 2, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Sirukumab in Confirmed COVID-19 Severe Disease	\$1,446,334.78
Thromboprophylaxis, risk factors and outcomes in COVID-19 infected hospitalized adults	\$61,986.25

<b>Eli Lilly and Company</b>	<b>\$44,889,437.20</b>
A PHASE 3 RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF LY3819253 IN PREVENTING SARS COV 2 INFECTION AND COVID 19 IN SKILLED NURSING AND ASSISTED LIVING FACILITY RESIDENTS AND STAFF A NIAID AND LILLY COLLABORATIVE STUDY	\$5,833,263.89
A RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED, PARALLEL GROUP PHASE 3 STUDY OF BARICITINIB IN PATIENTS WITH COVID 19 INFECTION	\$6,665,186.16
A RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED, PHASE 2 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF LY3819253 AND LY3832479 IN PARTICIPANTS WITH MILD TO MODERATE COVID-19 ILLNESS	\$29,549,136.62
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, CLINICAL TRIAL OF LY3127804 IN PATIENTS WHO ARE HOSPITALIZED WITH PNEUMONIA AND PRESUMED OR CONFIRMED COVID-19	\$1,647,343.00
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF MONO AND COMBINATION THERAPY WITH MONOCLONAL ANTIBODIES IN PARTICIPANTS WITH MILD TO MODERATE COVID-19 ILLNESS (BLAZE-4)	\$307,419.19
A RANDOMIZED, PLACEBO CONTROLLED, DOUBLE BLIND, SPONSOR UNBLINDED, SINGLE ASCENDING DOSE, PHASE 1 FIRST IN HUMAN STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS AND PHARMACODYNAMICS OF INTRAVENOUS LY3819253 IN PARTICIPANTS HOSPITALIZED FOR COVID 19	\$734,396.17
ADAPTIVE PLATFORM TREATMENT TRIAL FOR OUTPATIENTS WITH COVID-19	\$1,591.09
BARICITINIB COMBINED WITH ANTIVIRAL THERAPY IN SYMPTOMATIC PATIENTS INFECTED BY COVID-19: AN OPEN-LABEL, PILOT STUDY	\$151,101.08
<b>Novartis Pharmaceuticals Corporation</b>	<b>\$22,189,335.53</b>
PHASE 3 MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFICACY AND SAFETY OF CANAKINUMAB ON CYTOKINE RELEASE SYNDROME IN PATIENTS WITH COVID-19-INDUCED PNEUMONIA (CAN-COVID)	\$21,658,979.23
TARGETING VASCULAR INFLAMMATION IN MODERATE COVID-19 WITH CRIZANLIZUMAB: A RANDOMIZED PLACEBO-CONTROLLED DOUBLE-BLIND TRIAL	\$530,356.30
<b>Gilead Sciences, Inc.</b>	<b>\$8,085,747.76</b>
A Multi-center, Multi-country Retrospective Cohort Study to Evaluate the Clinical Outcomes in Adults with Severe COVID-19	\$3,877,323.00
A Phase 1b/2a study in A Phase 1b/2a Study in Participants with Early Stage COVID-19 to Evaluate the Safety, Efficacy, and Pharmacokinetics of Remdesivir Administered by Inhalation	\$1,326,056.77
A Phase 2/3 Single-Arm, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of Remdesivir (GS-5734) in Participants from Birth to < 18 Years of Age with COVID-19	\$1,259,398.82
Phase 3 Randomized Double-Blind Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Remdesivir (GS-5734) treatment of COVID-19 in an outpatient setting	\$1,522,969.17
SARS-COV-2 Virus Neutralization Assay	\$100,000.00
<b>Roche Products Limited</b>	<b>\$7,295,459.79</b>
COVACTA ACTEMRA COVID 19 PNEUMONIA STUDY	\$7,295,459.79
<b>Hoffmann-La Roche Limited</b>	<b>\$7,007,616.72</b>
SAFETY EFFICACY OF A COMBINATION OF REMDESIVIR TOCILIZUMAB IN SEVERE COVID 19 PNEUMONIA	\$7,007,616.72

<b>Incyte Corporation</b>	<b>\$6,428,321.85</b>
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Ruxolitinib in Participants With COVID-19-Associated ARDS Who Require Mechanical Ventilation (RUXCOVID-DEVENT)	\$6,289,335.85
Interventional Study to Evaluate the Efficacy of Therapeutic Plasma Exchange (TPE) Alone or in Combination with Ruxolitinib in COVID-19 Positive Patients with PENN Grade 2, 3, 4 Cytokine Released Syndrome (CRS)	\$138,986.00
<b>Genentech, Inc.</b>	<b>\$5,889,814.73</b>
FIBRINOLYTIC THERAPY TO TREAT ARDS IN THE SETTING OF COVID 19 INFECTION A PHASE 2A CLINICAL TRIAL	\$288,712.00
PHII IL22FC ANTI ST2 IN SEVERE COVID 19 PNEUMONIA	\$2,976,210.82
TNK TPA IN PATIENTS WITH COVID 19	\$42,456.66
TOCILIZUMAB THERAPY FOR COVID 19 PNEUMONIA IN HOSPITALIZED PATIENTS	\$2,582,435.25
<b>Abbott Laboratories</b>	<b>\$3,547,836.99</b>
Abbott RealTime SARS-CoV-2 Reproducibility and Clinical Testing Study	\$294,479.75
Abbott RealTime SARS-CoV-2 Specimen Collection Protocol	\$15,000.00
Alinity m SARS CoV-2 assay evaluation of saliva sample type	\$134,381.64
Alinity m SARS CoV-2 assay evaluation on Alinity m system	\$20,454.00
Alinity m SARS-CoV-2 Reproducibility and Testing Study	\$9,722.56
Characterization of SARS-CoV-2 Serology Profile in Pediatric Patients	\$7,496.00
Clinical evaluation of the ID NOW COVID-19 Assay	\$930,386.85
Clinical Evaluation of the Panbio COVID-19 Ag AnTigen (Ag) Assay in Symptomatic Subjects (CATSS)	\$229,861.21
Evaluation of ARCHITECT IgG Qualitative Performance on COVID-19 Convalescent Plasma Specimens & Controls	\$8,728.49
Evaluation of Oncology Patients for Evidence of SARS-CoV-2 IgG Seroconversion	\$5,297.00
ID NOW COVID-19	\$922,119.98
Inpatient CGM use for COVID-19 - a reduction in healthcare worker contact risk	\$1,441.32
Longitudinal, Observational Registry of Persons Under Investigation for SARS-CoV2: The RUSH-COVID-19 Study	\$130,000.00
Panbio COVID-19 Rapid Test Device Fingertstick and near Patient Study	\$273,032.50
Performance and Comparison Evaluation of ARCHITECT SARS-CoV-2 IgG Assay	\$62,271.00
Performance Evaluation of ARCHITECT SARS-CoV-2 IgG and IgM vs Alinity SARS-CoV-2 IgG and IgM assays	\$131,198.06
Performance Evaluation of ARCHITECT SARS-CoV-2 IgM	\$164,885.63
RealTime SARS CoV-2 assay evaluation of saliva sample type	\$35,824.00
Sampling Employees at Rush University Medical Center and First Responders in Chicago for Evidence of SARS-CoV-2 Seroconversion (IgG and IgM)	\$65,650.00

SARS COV-2 quantitative evaluation on m2000sp/rt	\$15,024.00
Serum ImmunoGlobulin SIG-COVID investigation for COVID-19 healthcare workers at BMC	\$31,947.00
Surveillance of Covid-19 exposures during early pregnancy in Rhode Island	\$31,391.00
The COVID-19 FIRE Study: First-responder Immune Response Evolution after SARS-Cov-2 Exposure	\$27,245.00
<b>Karyopharm Therapeutics Inc.</b>	<b>\$3,485,792.15</b>
XPORT-COV-1001	\$3,485,792.15
<b>Covis Pharma GmbH</b>	<b>\$2,861,004.97</b>
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of Ciclesonide Metered-Dose Inhaler in Non-Hospitalized Patients 12 Years of Age and Older With Symptomatic COVID-19 Infection	\$2,861,004.97
<b>BeiGene, Ltd.</b>	<b>\$2,406,424.64</b>
A Phase 2, Randomized, Double Blind, Placebo-Controlled Study of Zanubrutinib Treatment in Patients Hospitalized for COVID 19 Infection and Pulmonary Distress	\$1,901,750.36
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of SARS-CoV-2 Neutralizing Antibody BGB-DXP593 in Patients WithMild-to-Moderate COVID-19	\$82,650.00
Treatment of Patients Hospitalized for COVID-19 Infection and Pulmonary Distress with Zanubrutinib	\$422,024.28
<b>Grifols Therapeutics LLC</b>	<b>\$1,536,984.80</b>
A Multicenter, Randomized, Open-label Parallel Group Pilot Study to Evaluate Safety and Efficacy of High Dose Intravenous Immune Globulin IVIG Plus Standard Medical Treatment SMT Versus SMT Alone in Subjects With COVID-19 Requiring Admission to the In	\$1,536,984.80
<b>Vanda Pharmaceuticals Inc.</b>	<b>\$1,491,799.70</b>
CALYPSO: WHOLE GENOME SEQUENCING ANALYSIS OF SARS-COV-2 POSITIVE PATIENTS	\$61,084.00
ODYSSEY: A STUDY TO INVESTIGATE THE EFFICACY OF TRADIPITANT IN TREATING SEVERE OR CRITICAL COVID-19 INFECTION	\$1,430,715.70
<b>Takeda Pharmaceuticals U.S.A., Inc.</b>	<b>\$1,357,352.89</b>
A PHASE 1B, RANDOMIZED, DOUBLE-BLIND, SINGLE AND REPEAT DOSING STUDY TO EVALUATE THE SAFETY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF LANADELUMAB WHEN ADDED TO STANDARD-OF-CARE IN SUBJECTS HOSPITALIZED WITH COVID-19 PNEUMONIA	\$51,723.00
A STUDY TO EVALUATE THE SAFETY, TOLERABILITY AND PHARMACOKINETICS (PK) OF TAK-981 IN ADULT PARTICIPANTS WITH ADVANCED OR METASTATIC SOLID TUMORS OR RELAPSED/REFRACTORY HEMATOLOGIC MALIGNANCIES AND IN A SUBSET WITH CORONAVIRUS DISEASE 2019 (COVID-19)	\$1,305,629.89
<b>AstraZeneca UK Limited</b>	<b>\$1,116,255.20</b>
A Phase III Randomized Double-blind Placebo-controlled Multi-center Study in Adults to Determine the Safety and Efficacy of AZD7442 a Combination Product of Two Monoclonal Antibodies (AZD8895 and AZD1061) for Pre-exposure Prophylaxis of COVID-19	\$1,090,053.20
A Phase III Randomized Double-blind Placebo-controlled Multi-center Study in Adults to Determine the Safety and Efficacy of AZD7442 a Combination Product of Two Monoclonal Antibodies AZD8895 and AZD1061 for Post-exposure Prophylaxis of COVID-19	\$26,202.00

<b>SANOFI PASTEUR INC.</b>	<b>\$892,509.48</b>
Study of Recombinant Protein Vaccine Formulations Against COVID-19 in Healthy Adults 18 Years of Age and Older	\$892,509.48
<b>Merck Sharp &amp; Dohme Corporation</b>	<b>\$831,931.13</b>
Analysis of Immune and Organ Systems Responses in Patients, with COVID-19	\$365,572.43
Burden of COVID-19	\$177,100.00
Human Immunity to SARS-CoV-2 after convalescence	\$39,559.78
Impact of COVID-19 on Immunocompromised Hosts	\$71,587.99
SARS-CoV-2 Immune Surveillance Among a Population Based Sample of Adults in Florida	\$178,110.93
<b>Boehringer Ingelheim Pharmaceuticals, Inc.</b>	<b>\$830,782.33</b>
Nintedanib for Sub Acute Lung Injury in COVID 19 P	\$529,721.78
TRPC6i in hospitalized patients with COVID 19	\$301,060.55
<b>Alexion Pharmaceuticals, Inc.</b>	<b>\$699,430.10</b>
A Phase 3 Open-label, Randomized, Controlled Study to Evaluate the Efficacy and Safety of Intravenously Administered Ravulizumab Compared With Best Supportive Care in Patients With COVID-19 Severe Pneumonia, Acute Lung Injury, or Acute Respiratory Distress	\$570,418.10
SOLIRIS (eculizumab) for the Treatment of Participants with Coronavirus Disease 2019 (COVID-19) An Expanded Access Program for Hospital-based Emergency Treatment.	\$129,012.00
<b>Amgen Inc.</b>	<b>\$664,202.32</b>
AMG 407 (OTEZLA) - Ph 3 COVID Consortium Study	\$4,198.70
I-SPY COVID TRIAL: An Adaptive Platform Trial to Reduce Mortality and Ventilator Requirements for Critically Ill Patients	\$660,003.62
<b>E.R. Squibb &amp; Sons, L.L.C.</b>	<b>\$373,533.90</b>
COVID-19 Registry to Assess Frequency, Risk Factors, Management, and Outcomes of Arterial and Venous Thromboembolic Complications CORONA-VTE NETWORK	\$18,900.00
Phase II, IV Abatacept in Hospitalized COVID-19 Participants with Respiratory Compromised with severe COVID-19 pneumonia	\$282,633.90
THE IMPACT OF ABATACEPT ON COVID-19 INFECTIONS IN PATIENTS WITH RHEUMATIC DISEASES	\$72,000.00
<b>AKEBIA THERAPEUTICS INC</b>	<b>\$352,669.57</b>
VADADUSTAT FOR THE PREVENTION AND TREATMENT OF ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) IN HOSPITALIZED PATIENTS WITH CORONAVIRUS DISEASE 2019 (COVID-19)	\$352,669.57
<b>Eli Lilly Export S.A. Puerto Rico Branch</b>	<b>\$323,066.00</b>
A RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED, PARALLEL GROUP PHASE 3 STUDY OF BARICITINIB IN PATIENTS WITH COVID 19 INFECTION	\$300,865.00
A RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED, PHASE 2 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF LY3819253 AND LY3832479 IN PARTICIPANTS WITH MILD TO MODERATE COVID-19 ILLNESS	\$22,201.00



<b>Beckman Coulter, Inc.</b>	<b>\$304,286.00</b>
COVID Immunity monitoring	\$50,000.00
COVID MDW - Sepsis	\$56,139.00
COVID-19 CTA	\$125,000.00
COVID-19 Neutralizing Antibodies	\$61,255.00
Pediatric MIS-C COVID-19 BARDA Trial	\$6,465.00
Retrospective analysis of antibody responses in COVID-19 patients	\$5,427.00
<b>Biogen, Inc.</b>	<b>\$235,523.27</b>
A global survey of multiple sclerosis providers to assess practice and prescribing changes due to the SARS-CoV-2 pandemic of 2020	\$36,525.00
The 2020 COVID-19 Pandemic and Multiple Sclerosis: Knowledge, Attitudes, and Practices of Patients	\$74,030.00
Understanding MS patients behavior, exposure risk and MS treatment during SARS-CoV-2 pandemic at CCF/LV	\$26,719.26
Understanding MS patients behavior, exposure risk and MS treatment during SARS-CoV-2 pandemic at NYU	\$26,763.90
Understanding MS patients behavior, exposure risk and MS treatment during SARSCoV-2 pandemic at OhioHealth	\$8,916.38
Understanding MS patients behavior, exposure risk and MS treatment during SARSCoV-2 pandemic at Washington University	\$62,568.73
<b>Celularity Inc.</b>	<b>\$217,140.34</b>
A Phase I II Study of Human Placental Hematopoietic Stem Cell Derived Natural Killer Cells (CYNK-001) for the Treatment of Adults With COVID-19	\$217,140.34
<b>Jazz Pharmaceuticals Inc.</b>	<b>\$216,036.15</b>
DEFIBROTIDE THERAPY FOR SARS-COV2 ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS)	\$216,036.15
<b>Grifols Shared Services North America, Inc.</b>	<b>\$199,922.00</b>
Antithrombin III AT3 in infectious disease caused by severe acute respiratory syndrome coronavirus 2 SARS-CoV-2	\$199,922.00
<b>Heron Therapeutics, Inc.</b>	<b>\$178,488.83</b>
Aprepitant Injectable Emulsion in Patients With COVID-19 (GUARDS-1)	\$178,488.83
<b>FUJIFILM SonoSite, Inc.</b>	<b>\$157,146.00</b>
Artificial Intelligence for Prognosis of Ultrasound of the Lung in COVID (AI PULL)	\$157,146.00
<b>Mallinckrodt Hospital Products Inc.</b>	<b>\$135,000.00</b>
INHALED NITRIC OXIDE GAS THERAPY IN MECHANICALLY VENTILATED PATIENTS AFFECTED BY SEVERE ACUTE RESPIRATORY SYNDROME IN COVID-19	\$135,000.00
<b>Varian Medical Systems, Inc.</b>	<b>\$125,625.00</b>
AI tool for lung changes CoV - Montefiore MCr	\$90,000.00
Investigation during COVID19 - CARES	\$15,625.00
PHASE II Patients w SARS-CoV-2 Pneumonia - Ohio St	\$20,000.00

<b>GE HEALTHCARE</b>	<b>\$99,842.58</b>
COVID-19 LONGITUDINAL MULTIETHNIC BIOIMAGING ASSESSMENT OF CARDIOVASCULAR SEQUELE (COLUMBIA CARDS) REGISTRY PILOT STUDY	\$15,340.58
EVALUATION OF PATIENTS ECG TO DETECT RISK FOR COVID-19	\$59,502.00
THE FEASIBILITY AND IMPORTANCE OF IMMEDIATE POST-STRESS IMAGING WITH TETROFOSMIN IN THE ERA OF COVID-19	\$25,000.00
<b>SANOFI US SERVICES INC.</b>	<b>\$94,805.47</b>
A Phase 1b, Randomized, Double-blinded, Placebo-controlled Study of Hydroxychloroquine in Outpatient Adults With COVID-19	\$70,455.00
A Phase 1b, Randomized, Double-blinded, Placebo-controlled Study to Evaluate the Safety and Immunomodulatory Effect of the RIPK1 Inhibitor SAR443122 in Hospitalized Patients With Severe COVID-19	\$10,309.50
Collection of COVID-19 Convalescent Serum Samples From Adults 18 Years of Age and Older	\$14,040.97
<b>Allergan, Inc.</b>	<b>\$91,678.00</b>
A RANDOMIZED CONTROLLED SINGLE BLIND CROSS OVER TRIAL EVALUATING THE IMPACT OF BOTOX TREATMENT INTO THE UPPER ONE THIRD OF THE FACE (GLABELLA, FOREHEAD, CROWS FEET) AN AREA ON MOOD AND SELF-APPEARANCE SATISFACTION IN A POST COVID PERIOD ON NON-NA?VE BOTOX PATIENTS WHO HAVE NOT HAD A BOTOX TREATMENT IN GREATER THAN 20 WEEKS.	\$62,090.00
Impact of Botox treatment on mood and self-appearance satisfaction in non-naive post Covid-19	\$22,838.00
IMPACT OF COVID-19 ON RETINAL DISEASES TREATED WITH OZURDEX	\$6,750.00
<b>PTC Therapeutics, Inc.</b>	<b>\$91,113.39</b>
EVALUATION OF THE EFFICACY AND SAFETY OF PTC299 IN HOSPITALIZED SUBJECTS WITH COVID-19	\$91,113.39
<b>ARRAY BIOPHARMA INC</b>	<b>\$76,847.00</b>
INVESTIGATION OF TOFACITINIB TO MITIGATE THE IMPACT OF COVID19 ITOMIC IN MODERATE SARSCOV2 MODERATE ITOMIC	\$76,847.00
<b>Rigel Pharmaceuticals, Inc.</b>	<b>\$76,309.25</b>
fostamatinib in hospitalized COVID patients	\$76,309.25
<b>Medtronic Vascular, Inc.</b>	<b>\$67,375.00</b>
COVID Response Strategies for Hospital and Urgent Care Settings Pilot	\$67,375.00
<b>Provepharm Inc.</b>	<b>\$66,150.00</b>
MB improves outcomes w/patients with Covid 19	\$66,150.00
<b>Becton, Dickinson and Company</b>	<b>\$64,675.13</b>
MAX COVID EUA FDA Response	\$54,004.44
Max Respiratory Panel COVIDFLURSV	\$3,020.00
SARS-CoV-2 sample type	\$7,650.69



<b>Hill-Rom Company, Inc</b>	<b>\$62,281.00</b>
A Novel Proportional Open Ventilation (POV) Device and Its Efficacy in Managing Acute Respiratory Failure in COVID-19 Patients	\$24,725.00
A Pilot Study of the Use of Oscillation and Lung Expansion (OLE) Therapy in Patients Hospitalized with COVID-19	\$16,756.00
A Pilot Study of Use of Oscillation and Lung Expansion (OLE) Therapy in Patients Admitted for COVID-19	\$20,800.00
<b>Brahms GmbH</b>	<b>\$50,813.00</b>
COVID-19 Study	\$50,813.00
<b>CONMED Corporation</b>	<b>\$48,010.30</b>
Risk of aerosolization of COVID-19 during surgery	\$48,010.30
<b>Lexicon Pharmaceuticals, Inc.</b>	<b>\$39,750.00</b>
SARS-CoV-2	\$39,750.00
<b>Biohaven Pharmaceuticals, Inc.</b>	<b>\$36,120.60</b>
Phase 2/3: Double-Blind, Randomized, Placebo Controlled, Safety and Efficacy Trial of Zavegepant (BHV-3500) Intranasal (IN) for Hospitalized Patients with COVID-19 Requiring Supplemental Oxygen	\$36,120.60
<b>Sagent Pharmaceuticals, Inc.</b>	<b>\$36,000.00</b>
Novel Agents for Treatment of High-risk COVID-19 Positive Patients	\$36,000.00
<b>Innovative Health Solutions, Inc.</b>	<b>\$31,549.00</b>
Covid Research Olive View UCLA	\$31,549.00
<b>Sandoz Inc.</b>	<b>\$23,490.00</b>
HYDROXYCHLOROQUINE FOR COVID-19 POST-EXPOSURE PROPHYLAXIS (PEP)	\$1,800.00
OUTCOMES RELATED TO COVID-19 TREATED WITH HYDROXYCHLOROQUINE AMONG IN-PATIENTS WITH SYMPTOMATIC DISEASE (ORCHID)	\$810.00
PATCH 2&3:PREVENTION & TREATMENT OF COVID-19 (SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2) WITH HYDROXYCHLOROQUINE	\$11,880.00
THE PATCH TRIAL (PREVENTION AND TREATMENT OF COVID-19 WITH HYDROXYCHLOROQUINE) (PATCH)	\$9,000.00
<b>BioFire Defense, LLC</b>	<b>\$15,350.00</b>
SARS-CoV-19 Regulatory Studies	\$15,350.00
<b>Siemens Medical Solutions USA, Inc.</b>	<b>\$12,500.00</b>
An Evaluation of the OnSite??? COVID-19 IgG/IgM Rapid Test in Point of Care Settings	\$12,500.00
<b>Dexcom, Inc.</b>	<b>\$11,687.86</b>
HUSTON METHODIST COVID	\$665.88
UTILITY OF CONTINUOUS GLUCOSE MONITORS IN THE MANAGEMENT OF INSULIN DRIP IN COVID PATIENTS	\$11,021.98

<b>Emergent BioSolutions Inc.</b>	<b>\$6,950.00</b>
COV	\$6,950.00
<b>ExThera Medical Corporation</b>	<b>\$1,633.50</b>
Seraph-100 Microbind Affinity Blood Filter for the Treatment of COVID-19 Under Emergency Use Authorization: Data Registry	\$1,633.50
<b>Sage Therapeutics, Inc.</b>	<b>\$1,475.00</b>
A STUDY OF BREXANOLONE FOR ACUTE RESPIRATORY DISTRESS SYNDROME DUE TO COVID-19	\$1,475.00
<b>Kyowa Kirin, Inc.</b>	<b>\$1,002.00</b>
Selective Estrogen Modulation and Melatonin in Early COVID-19 ( aka Sentinel	\$1,002.00
<b>CSL Behring</b>	<b>\$900.00</b>
Laboratory Testing for COVID Project	\$900.00
<b>Grand Total</b>	<b>\$525,344,219.30</b>